Increased serum levels of soluble CD14 indicate stable multiple sclerosis

Area of Science:

• Neuroimmunology
• Biomarker Discovery
• Inflammatory Diseases

Background:

• Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system.
• The role of specific immune markers, such as soluble CD14 (sCD14), in MS pathogenesis remains to be fully elucidated.
• Understanding novel biomarkers can aid in disease monitoring and therapeutic strategies.

Purpose of the Study:

• To investigate the potential involvement of soluble CD14 (sCD14) in the context of multiple sclerosis (MS).
• To compare sCD14 serum levels across different MS subtypes and disease states.
• To assess the impact of interferon-beta treatment on sCD14 expression.

Main Methods:

• Serum samples were collected from MS patients and control groups (neurological and healthy).
• Soluble CD14 (sCD14) levels were quantified using enzyme-linked immunosorbent assay (ELISA).
• Statistical analyses were performed to compare sCD14 levels between groups and disease conditions.

Main Results:

• Significantly higher serum sCD14 levels were observed in MS patients compared to both neurological and healthy controls.
• Within the MS cohort, sCD14 levels were elevated in relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) relative to primary progressive MS (PPMS).
• sCD14 concentrations were also found to be increased during stable disease phases and following interferon-beta treatment.

Conclusions:

• Serum sCD14 is elevated in multiple sclerosis (MS) patients, suggesting its potential as a biomarker.
• sCD14 levels correlate inversely with disease activity in relapsing MS, indicating a complex relationship with disease progression.
• These findings highlight sCD14 as a potential indicator of disease presence and a modulator of immune responses in MS.